Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Apr

Today In Oncology

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos